rheumatology
Rheumatoid Arthritis Management
DMARD initiation, DAS28 monitoring, and biologic escalation for RA
Source: NICE CG79 2018 / EULAR 2022
Step 1 of ~7
info
RA Diagnosis
2010 ACR/EULAR criteria: joint involvement, serology (RF/ACPA), acute-phase reactants, duration. Calculate score ≥6 = definite RA. Refer to rheumatology within 3 weeks of suspicion.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Hydroxychloroquine · Aminoquinoline — Malaria Prophylaxis / SLE / Rheumatoid Arthritis
- Adalimumab · Biologic DMARD (TNF-alpha inhibitor, monoclonal antibody)
- Tocilizumab · Biologic DMARD (IL-6 receptor antagonist)
- Rituximab (Rheumatology) · Biologic DMARD — Anti-CD20
- Sarilumab · Biologic DMARD — IL-6 Receptor Antagonist
- Guselkumab · Biologic DMARD — IL-23 Inhibitor (Anti-p19)
Pathways
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Gout Management · EULAR 2016 / BSR 2017
Decision support only. Always apply local guidelines and clinical judgement.